OPR - Delayed Quote • USD MYGN May 2024 18.000 call (MYGN240517C00018000) Follow 1.9000 0.0000 (0.00%) As of April 16 at 2:19 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for MYGN240517C00018000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: MYGN Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen Myriad Genetics (MYGN) Announces Favorable Research Results Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound? Why Is Myriad (MYGN) Down 1% Since Last Earnings Report? Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
